Maraviroc
Active ingredient: Maraviroc
In short: Maraviroc tablets are indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients 2 years of age and older weighing at least 10 kg. Limitations of Use: Maraviroc tablets are not
What is Maraviroc used for?
Maraviroc tablets are indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients 2 years of age and older weighing at least 10 kg.
Limitations of Use:
Maraviroc tablets are not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1 .
âš Boxed warning (FDA's strongest warning)
Hepatotoxicity has been reported with use of maraviroc tablets. Severe rash or evidence of a systemic allergic reaction (e.g., fever, eosinophilia, or elevated IgE) prior to the development of hepatotoxicity may occur. Patients with signs or symptoms of hepatitis or allergic reaction following use of maraviroc tablets should be evaluated immediately .
Maraviroc dosage
Prior to initiation of maraviroc tablets for treatment of HIV-1 infection, test all patients for CCR5 tropism using a highly sensitive tropism assay. Maraviroc tablets are recommended for patients with only CCR5-tropic HIV-1 infection. Outgrowth of pre-existing low-level CXCR4- or dual/mixed-tropic HIV-1 not detected by tropism testing at screening has been associated with virologic failure on maraviroc tablets .
Monitor patients for ALT, AST, and bilirubin prior to initiation of maraviroc tablets and at other time points during treatment as clinically indicated .
Maraviroc tablets are taken twice daily by mouth and may be taken with or without food.
Maraviroc tablets must be given in combination with other antiretroviral medications.
The recommended dosage of maraviroc tablets differs based on concomitant medications due to drug interactions.
Table 1 displays oral dosage of maraviroc tablets based on different concomitant medications .
Concomitant Medications | Dosage of Maraviroc
Potent cytochrome P450 (CYP)3A inhibitors (with or without a potent CYP3A inducer)Potent CYP3A inhibitors (with or without a potent CYP3A inducer) including: clarithromycin, cobicistat, elvitegravir/ritonavir, itraconazole, ketoconazole, nefazodone, protease inhibitors (except tipranavir/ritonavir), telithromycin. | 150 mg twice daily
Noninteracting concomitant medicationsNoninteracting concomitant medications include all medications that are not potent CYP3A inhibitors or inducers such as: dolutegravir, enfuvirtide, nevirapine, all nucleoside reverse transcriptase inhibitors (NRTIs), raltegravir, and tipranavir/ritonavir. | 300 mg twice daily
Potent and moderate CYP3A inducers (without a potent CYP3A inhibitor)Potent and moderate CYP3A inducers (without a potent CYP3A inhibitor) including: carbamazepine, efavirenz, etravirine, phenobarbital, phenytoin, and rifampin. | 600 mg twice daily
The recommended dosage of maraviroc tablets should be based on body weight (kg) and should not exceed the recommended adult dose. The recommended dosage also differs based on concomitant medications due to drug interactions (Table 2 and Table 3) .
Before prescribing maraviroc tablets, assess children for the ability to swallow tablets. If a child is unable to reliably swallow maraviroc tablets, the oral solution formulation should be prescribed.
The recommended oral dosage of maraviroc tablets in pediatric patients aged 2 years and older weighing at least 10 kg is presented in Table 2. …
How to take Maraviroc — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Hepatotoxicity
Inform patients that hepatotoxicity, including life-threatening cases, has been reported with maraviroc tablets; therefore, it is important to inform the healthcare professional if patients have underlying hepatitis B or C or elevations in liver-associated tests prior to treatment. Inform patients to stop maraviroc tablets and seek medical evaluation immediately if they develop signs or symptoms of hepatitis or allergic reaction following use of maraviroc tablets. Advise patients that laboratory tests for liver enzymes and bilirubin will be ordered prior to starting maraviroc tablets, at other times during treatment, and if they develop severe rash or signs and symptoms of hepatitis or an allergic reaction on treatment .
Cardiovascular Events
When administering maraviroc tablets in patients with cardiovascular comorbidities, a history of postural hypotension or receiving concomitant medication known to lower blood pressure, advise patients that they may be at increased risk for cardiovascular events. …
Warnings & precautions
Do not take this medicine if: Maraviroc tablets are contraindicated in patients with severe renal impairment or ESRD (CrCl less than 30 mL per minute) who are concomitantly taking potent CYP3A inhibitors or inducers .
Hepatotoxicity with allergic features including life-threatening events has been reported in clinical trials and postmarketing. Severe rash or evidence of systemic allergic reaction including drug-related rash with fever, eosinophilia, elevated IgE, or other systemic symptoms have been reported in conjunction with hepatotoxicity . These events occurred approximately 1 month after starting treatment. Among reported cases of hepatitis, some were observed in the absence of allergic features or with no pre-existing hepatic disease.
Appropriate laboratory testing including ALT, AST, and bilirubin should be conducted prior to initiating therapy with maraviroc tablets and at other time points during treatment as clinically indicated. Hepatic laboratory parameters should be obtained in any patient who develops rash, or signs or symptoms of hepatitis, or allergic reaction. Discontinuation of maraviroc tablets should be considered in any patient with signs or symptoms of hepatitis, or with increased liver transaminases combined with rash or other systemic symptoms.
When administering maraviroc tablets to patients with pre-existing liver dysfunction or who are coinfected with hepatitis B and/or C virus, additional monitoring may be warranted. The safety and efficacy of maraviroc tablets have not been specifically studied in patients with significant underlying liver disorders.
Severe, potentially life-threatening skin and hypersensitivity reactions have been reported in patients taking maraviroc tablets, in most cases concomitantly with other drugs associated with these reactions. …
Maraviroc side effects
The following adverse reactions are discussed in other sections of the labeling:
Hepatotoxicity
Severe Skin and Hypersensitivity Reactions
Cardiovascular Events
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Clinical Trials Experience in Adult Subjects
Treatment-Experienced Subjects: The safety profile of maraviroc tablets is primarily based on 840 HIV-1-infected subjects who received at least 1 dose of maraviroc tablets during two Phase 3 trials. A total of 426 of these subjects received the indicated twice-daily dosing regimen.
Assessment of treatment-emergent adverse events is based on the pooled data from 2 trials in subjects with CCR5-tropic HIV-1 (A4001027 and A4001028). The median duration of therapy with maraviroc tablets for subjects in these trials was 48 weeks, with the total exposure on maraviroc tablets twice daily at 309 patient-years versus 111 patient-years on placebo each administered with optimized background therapy (OBT). The population was 89% male and 84% white, with mean age of 46 years (range: 17 to 75 years). Subjects received dose equivalents of 300 mg maraviroc once or twice daily. …
Drug interactions
Maraviroc is metabolized by CYP3A and is also a substrate for P-glycoprotein (P-gp), organic anion-transporting polypeptide (OATP)1B1, and multidrug resistance-associated protein (MRP)2. The pharmacokinetics of maraviroc are likely to be modulated by inhibitors and inducers of CYP3A and P-gp and may be modulated by inhibitors of OATP1B1 and MRP2. Therefore, a dosage adjustment may be required when maraviroc is coadministered with those drugs .
Concomitant use of maraviroc and St. John's wort (Hypericum perforatum) or products containing St. John's wort is not recommended. Coadministration of maraviroc with St. John's wort is expected to substantially decrease maraviroc concentrations and may result in suboptimal levels of maraviroc and lead to loss of virologic response and possible resistance to maraviroc.
Additional drug interaction information is available .
About this medicine
Maraviroc is a selective, slowly reversible, small molecule antagonist of the interaction between human CCR5 and HIV-1 gp120. Blocking this interaction prevents CCR5-tropic HIV-1 entry into cells.
Maraviroc tablets (film-coated) for oral administration contain 150 or 300 mg of maraviroc and the following inactive ingredients: dibasic calcium phosphate (anhydrous), magnesium stearate, microcrystalline cellulose, silicon dioxide, and sodium starch glycolate. The film coat (Opadry II Blue [85G20583]) contains FD&C blue #2 aluminum lake, lecithin, polyethylene glycol (macrogol 3350), polyvinyl alcohol, talc, and titanium dioxide.
Maraviroc is chemically described as 4,4-difluoro-N-{(1S)-3-[exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclohexanecarboxamide.
The molecular formula is C29H41F2N5O and the structural formula is:
Maraviroc is a white to pale-colored powder with a molecular weight of 513.67. It is highly soluble across the physiological pH range (pH 1.0 to 7.5).
How it works: Maraviroc is an HIV-1 antiviral drug . …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c35f72dc-d90e-43f8-9899-f7d1da89460d. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin